Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis

NCT03591094 is registered in ClinicalTrials.gov with Proteostasis Therapeutics, Inc. as lead sponsor.

NCT NCT03591094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis
Lead sponsor
Proteostasis Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 21, 2018
Completion date
February 18, 2019
Enrollment
40 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis